PMLT21057 / APEC1621F / Kazi
Research Question:
Does the drug ensartinib treat patients with solid tumors, non-Hodgkin lymphoma or
histiocytic disorders?
Basic Study Information
Purpose:
This phase II Pediatric MATCH trial studies how well ensartinib works in treating
patients with solid tumors, non-Hodgkin lymphoma, or histiocytic disorders with ALK
or ROS1 genomic alterations that have come back (recurrent) or does not respond to
treatment (refractory) and may have spread from where it first started to nearby tissue,
lymph nodes, or distant parts of the body (advanced). Ensartinib may stop the growth
of tumor cells by blocking some of the enzymes needed for cell growth.
Location: University of Rochester
Lead Researcher (Principal Investigator)
Lead Researcher:
Rafi Kazi
Study Contact Information
Study Contact: Clinical Trials Office
Study Location: Wilmot Cancer Institute, University of Rochester Medical Center
Study Email: WCICTOResearch@urmc.rochester.edu
Additional Study Details
Trial Not Found
The study you are looking for is not active at this time.
Return to Search